Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Sales Force Restructuring Boosts Operating Profit, Not Sales

Executive Summary

AstraZeneca's efforts to restructure its EU sales force have helped the company improve its margins

You may also be interested in...

J&J Acquisitions Governed By Payback Potential, Despite Credit “Uncertainty”

Maintaining a stellar credit rating is not a constraint on how much Johnson & Johnson is willing to spend on acquisitions, Chief Financial Officer Dominic Caruso said during the company's April 15 first quarter earnings call

AstraZeneca Settles Nexium Case With Ranbaxy; Can It Delay Other Generics?

AstraZeneca expects its settlement agreement with Ranbaxy ending Nexium (esomeprazole) patent infringement litigation will win a nod of approval from the Federal Trade Commission

AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches

AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts